Acute pulmonary embolism (PE) poses a significant burden on health and survival. Its
severity ranges from asymptomatic, incidentally discovered subsegmental thrombi to …

Objectives: Identify the causes of hypercoagulability. Describe the evaluation of a patient
with hypercoagulability. Summarize the treatment of hypercoagulability. Explain modalities …

Randomized controlled trials have shown that patients with venous thromboembolism
benefit from a minimum of three months of anticoagulant therapy. After this period, it was …

The US Surgeon General estimates that 100 000 to 180 000 deaths occur annually from
acute pulmonary embolism (PE) in the United States. The case of Ms A, a 60-year-old …

Purpose The aim of this study is to assess the feasibility of aspiration mechanical
thrombectomy in patients with massive and submassive pulmonary embolism (PE) and …

Background Data concerning the importance of a family history of venous thromboembolism
(VTE) for the risk of recurrent VTE are sparse. The aim of this nationwide study was to …

Venous thromboembolism (VTE) 3 traditionally has been considered a time-limited acute
disease. Patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) following …

Hypercoagulable and/or hypofibrinolytic states are risk factors for venous thromboembolism
(VTE) including acute pulmonary embolism. Current screening for thrombophilia is targeted …

Venous thromboembolism (VTE) recurrence carries significant mortality and morbidity.
Accurate risk assessment and effective treatment for patients with acute pulmonary …

Pulmonary embolism (PE) is the principal preventable cause of in-hospital deaths.
Prevalence of PE in Asians is uncertain but undoubtedly underestimated. Asians and …